Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Real-world edoxaban VTE data show low rates of bleeding and VTE events reported after 12 months of edoxaban treatmentDaiichi Sankyo2023-11-09 14:58:41Real-world edoxaban VTE data show low rates of bleeding and VTE events reported after 12 months of edoxaban
-
Daiichi Sankyo’s SANTORINI study gets underway, investigating cholesterol care across EuropeDaiichi Sankyo2023-11-09 20:56:10Daiichi Sankyo’s SANTORINI study gets underway, investigating cholesterol care across Europe
-
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2023-11-09 20:56:21Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA®
-
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research InstituteDaiichi Sankyo2020-07-24 10:37:21Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research
-
Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual MeetingDaiichi Sankyo2020-07-24 10:39:26Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting
-
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary EndpointDaiichi Sankyo2020-01-27 09:31:00Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
-
DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2 Positive Metastatic Breast Cancer TrialDaiichi Sankyo2020-07-24 10:46:06DS-8201 ([Fam-] Trastuzumab Deruxtecan) Achieved A Tumor Response Rate of 60.9% in Pivotal Phase 2 HER2
-
The Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid Completes Patient EnrolmentDaiichi Sankyo2019-12-12 16:00:02The Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid Completes Patient Enrolment
-
Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung CancerDaiichi Sankyo2019-12-12 16:00:02Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with
-
Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung CancerDaiichi Sankyo2019-12-12 16:00:02Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World
